TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05991375
Drug: DEXmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 28 mL of Bupivacain 0.25% was mixed with Dexmedetomidine 1 microgram/kg body weight mixed in 2 mL = total volume 30 mL
Study: NCT06496581
Drug: 177Lu-PMSA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once every 6 weeks, 7400 MBq 177Lu-PMSA-617 will be administered for up to a total of 4 cycles.
Study: NCT06354582
Drug: Vitamin C Injection
Normalized name: B-complex with vitamin C INJECTION VIAL (EA)
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Specification: 5ml: 1g. Method: parturients in each group will be intravenously injected with corresponding dose after receiving epidural labor analgesia.
Study: NCT06132165
Drug: Deoxycholic Acid
Normalized name: Deoxycholic Acid
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the cutaneous Neurofibromas lesion.
Study: NCT06132165
Drug: Polidocanol
Normalized name: Polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the cutaneous Neurofibromas lesion.
Study: NCT05576038
Drug: L-Tryptophan
Normalized name: L-tryptophan
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan is an essential amino acid responsible for activating the aryl hydrocarbon receptor (AhR). Dietary tryptophan is metabolized by the gut microbiota producing several 'indoles' such as (indole-3-aldehyde (IAld), indole-3-acetic acid (IAA), indole-3 propionic acid (IPA), indole-3-acetaldehyde (IAAld), indole-3-lactic acid (ILA) and indole-acrylic acid) and tryptamine, which are ligands for the AhR, a nuclear transcription factor involved in activating target genes responsible for maintaining gut integrity. Prior literature suggests that patients with active celiac disease have a lower functional capacity to produce these AhR ligands, which further impairs the AhR pathway. Hence, the aim of this study is to assess the effects of tryptophan supplementation in patients with celiac disease, non-responsive to a GFD for more than 1 year compared with the effects of an inactive, placebo comparator, L-leucine.
Study: NCT05570084
Drug: Silodosin
Normalized name: Silodosin
DrugBank: Silodosin (DB06207)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cap silodosin for medical expulsion therapy
Study: NCT05570084
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cap tamsulosin
Study: NCT05683964
Drug: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: per standard care
Study: NCT05648058
Drug: Nefopam ampule
Normalized name: nefopam
DrugBank: Nefopam (DB12293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: nefopam ampule 50 mg
Study: NCT05648058
Drug: diphenhydramine ampule
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: diphenhydramine ampule 10 mg
Study: NCT05975580
Drug: Topiramate
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate is an anticonvulsant (antiepilepsy) drug. IUPAC ID: 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
Study: NCT05975580
Drug: Phentermine
Normalized name: Phentermine
DrugBank: Phentermine (DB00191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phentermine belongs to a class of drugs called anorectics, also known as appetite suppressants. IUPAC name 2-methyl-1-phenylpropan-2-amine
Study: NCT06443502
Drug: Vedolizumab
Normalized name: Vedolizumab
DrugBank: Vedolizumab (DB09033)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Vedolizumab intravenous infusion.
Study: NCT06264414
Drug: Dutasteride-Tamsulosin
Normalized name: dutasteride-tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral route
Study: NCT05382299
Drug: Sacituzumab Govitecan-hziy
Normalized name: sacituzumab govitecan-hziy
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered intravenously
Study: NCT05382299
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05382299
Drug: nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously
Study: NCT05382299
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05382299
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT06463691
Drug: BGB-11417
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonrotoclax, orally, 320 mg once daily following a weekly ramp-up schedule
Study: NCT06463691
Drug: BGB-3111
Normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zanubrutinib, orally, 320 mg total daily dose
Study: NCT06463691
Drug: CD20
Normalized name: HuMax-CD20
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CD20mab is recommened as Rituximab as per the protocol, other CD20mab is also allowed.
Study: NCT03708549
Drug: Berberine
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will randomly assigned to receive berberine (900 mg day-1, three times a day) and metformin simulant（750mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
Study: NCT03708549
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients will randomly assigned to receive metformin (750 mg day-1, three times a day) and berberine simulant（900mg day-1, three times a day） on the basis of the second-generation antipsychotics monotherapy
Study: NCT05013112
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empagliflozin 20mg once daily from discharge
Study: NCT05013112
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin 500mg twice daily from discharge
Study: NCT05116475
Drug: Darolutamide 300 mg
Normalized name: darolutamide 300 MG
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
Study: NCT05037006
Drug: Sevoflurane - Neostigmine 30
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
Study: NCT05037006
Drug: Sevoflurane - Neostigmine 50
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
Study: NCT05037006
Drug: Sevoflurane - Neostigmine 70
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
Study: NCT05037006
Drug: TIVA - Neostigmine 30
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 30 mcg/kg and atropine 15 mcg/kg when TOFc 3
Study: NCT05037006
Drug: TIVA - Neostigmine 50
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 50 mcg/kg and atropine 25 mcg/kg when TOFc 3
Study: NCT05037006
Drug: TIVA - Neostigmine 70
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine 70 mcg/kg and atropine 35 mcg/kg when TOFc 3
Study: NCT05116475
Drug: Placebo of Darolutamide
Normalized name: darolutamide
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
Study: NCT06275763
Drug: Phase C: Torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomly assigned to this arm take Torasemide and placebos of Eplerenone and Spironolactone
Study: NCT04981314
Drug: Equinacea Arkopharma
Normalized name: Echinacea
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Echinacea hard caplets
Study: NCT04932252
Drug: A4368 or placebo tablet
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: orally administered
Study: NCT06153602
Drug: Nalbuphine Hydrochloride 10 MG/ML
Normalized name: nalbuphine hydrochloride 10 MG/ML
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalbuphine(10mg/ml) 0.8 mg intrathecal
Study: NCT06153602
Drug: Sodium Chloride 0.9 % in 5 ML Injection
Normalized name: sodium chloride 0.9 % in 5 ML Injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.9% Sodium Chloride 0.08 ml intrathecal
Study: NCT06153602
Drug: Bupivacaine Hydrochloride, Spinal
Normalized name: Bupivacaine Hydrochloride, Spinal
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% Hyperbaric or Isobaric Spinal Bupivacaine 1-4 ml intrathecal
Study: NCT06153602
Drug: Nalbuphine Hcl 10Mg/Ml Inj
Normalized name: NALBUPHINE HCL 10MG/ML INJ
DrugBank: Nalbuphine (DB00844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg IV prn for postoperative pain score\>=4 q 6 h
Study: NCT06153602
Drug: Ondansetron 8mg
Normalized name: ONDANSETRON 8MG ORAL DISINTEGRATING TAB
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg IV prn for nausea or vomiting q 8 h
Study: NCT04672291
Drug: Poly-ICLC (Hiltonol®) or Placebo
Normalized name: poly ICLC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The safety cohort (Cohort A) consists of 13 patients who will be randomized to receive 2 cycles of the study drug (N10) or 2 placebo cycles (N3).
Study: NCT04672291
Drug: Poly-ICLC (Hiltonol®) or Placebo
Normalized name: poly ICLC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The expansion cohort will receive 3 cycles of therapy. A total of 30 patients will be accrued and randomized 4:1 to receive drug (N=24) or placebo (N=6).
Study: NCT05070260
Drug: Intravenous glenzocimab (ACT017) 1000 mg
Normalized name: Glenzocimab
DrugBank: Glenzocimab (DB16175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on therapy to the standard of Care in the treatment of the acute ischemic stroke symptoms
Study: NCT06120400
Drug: Whole Egg
Normalized name: Whole Egg Allergen Extract 0.01 GM/1 ML Subcutaneous Solution
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole Large, Grade A Egg
Study: NCT04782271
Drug: SYL18001 sodium Low dose q.d
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the randomized eye once daily
Study: NCT04782271
Drug: SYL18001 sodium Middle dose q.d
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the randomized eye once daily
Study: NCT06197529
Drug: Topical alone (Capsaicin 8% Patch)
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4x4 patch
Study: NCT04782271
Drug: SYL18001 sodium High dose q.d
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the randomized eye once daily
Study: NCT04782271
Drug: SYL18001 sodium High dose b.i.d
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 drop in the randomized eye twice daily
Study: NCT05160350
Drug: Probiotic
Normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
Study: NCT05400122
Drug: Vactosertib
Normalized name: Vactosertib
DrugBank: Vactosertib (DB15310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vactosertib is a highly selective, potent inhibitor of the protein serine/threonine kinase activity of transforming growth factor (TGF)-β receptor type 1 (TGFBR1; also known as activin receptor-like kinase 5 \[ALK5\]). Vactosertib inhibits the phosphorylation of the ALK5 substrates Smad2 and Smad3, as well as the intracellular signaling of TGF-β.
Study: NCT05400122
Drug: Fludarabine Phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoroara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
Study: NCT02006173
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
Study: NCT00106548
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 4mg/kg iv / month
Study: NCT00106548
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv / month
Study: NCT05560282
Drug: Fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FINTEPLA oral solution contains 2.2 mg/mL fenfluramine, equivalent to 2.5 mg/mL of the hydrochloride salt. The active ingredient, fenfluramine hydrochloride, is designated chemically as N-ethyl-α- methyl-3-(trifluoromethyl) phenethylamine hydrochloride.~Fenfluramine hydrochloride is a white to off-white crystalline solid. The pKa of fenfluramine is 10.2. FINTEPLA is a clear, colorless solution, pH 5.
Study: NCT05658016
Drug: TK-112690
Normalized name: TK-112690
DrugBank: TK-112690 (DB18822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TK112690 treatment Pre \& Post Radiation
Study: NCT05661227
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Whether apply DEX or not
Study: NCT05661227
Drug: 0.9% Sodium chloride
Normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Whether apply DEX or not
Study: NCT05078138
Drug: Epoetin Alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous injection of Epoetin Alfa 3 times per week for 4 weeks
Study: NCT05898919
Drug: Neostigmine Injectable Product
Normalized name: neostigmine Injectable Product
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neostigmine was injected once after postoperative urinary retention.
Study: NCT06426056
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Study: NCT06426056
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemotherapy regimen included weekly cisplatin (40 mg/m\^2) and weekly nab-paclitaxel at escalating doses (33 mg/m\^2 per week).
Study: NCT00113776
Drug: ABX-EGF
Normalized name: ABX-EGF
DrugBank: Panitumumab (DB01269)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT06051240
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium sulphate, 42 mg (6 mmol lithium)
Study: NCT05319990
Drug: Aminohippurate Sodium Inj 20% Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PAH (Basic Pharma, Geleen, Netherlands) has been used to measure ERPF in human research for 7 decades, and is very well tolerated and generally recognized as safe with low toxicity.
Study: NCT05319990
Drug: Iohexol Inj 300 MG/ML Diagnostic aid/agent used to measure glomerular filtration rate (GFR)
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iohexol (Omnipaque 300, GE Healthcare, Chicago, IL) is a nonionic, low osmolar contrast agent with a history of extensive use in Radiology practice (for contrast x-rays) that shares many qualities of an ideal GFR marker, like inulin, such as not being absorbed, metabolized, or secreted by the kidney.
Study: NCT04662944
Drug: brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There was no treatment allocation. Patients administered Brolucizumab by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT04662944
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There was no treatment allocation. Patients administered Ranibizumab by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT04662944
Drug: aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: There was no treatment allocation. Patients administered Aflibercept by prescription that started before inclusion of the patient into the study were enrolled.
Study: NCT04642274
Drug: Fasting
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Take 10% glucose water 6ml/kg 2 to 4 hours before operation (except for diabetes).
Study: NCT05970185
Drug: G-CSF
Normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: G-CSF 5ug/kg/d from day 5 after the end of chemotherapy until the end of collection
Study: NCT05124314
Drug: Mifepristone, Oral, 200 Mg
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding 600 mg of oral Mifepristone to the regular treatment with vaginal Misoprostol 800 mcg
Study: NCT05124314
Drug: Misoprostol Pill
Normalized name: misoprostol Pill
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Regular treatment with vaginal Misoprostol 800 mcg
Study: NCT03764748
Drug: Washed Microbiota Transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The prepared microbiota suspension was infused into the participates' lower gut.
Study: NCT05523037
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the maintenance of anesthesia, the end-tidal concentration of 1 minimum alveolar concentration (MAC) sevoflurane and the concentration was adjusted by 1% stepwise titration
Study: NCT05523037
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For the maintenance of anesthesia, 1-2 mg.kg-1.h-1 of remimazolam was continuously infused.
Study: NCT05560373
Drug: Huperzine A injection, operational treatment, the best basic treatment
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular
Study: NCT05560373
Drug: Huperzine A injection, interventional treatment, the best basic treatment
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intramuscular
Study: NCT05664542
Drug: ropivacaine and dexmedetomidine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.2 % ropivacaine and dexmedetomidine
Study: NCT05862701
Drug: Permethrin
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5% permethrin cream
Study: NCT06287905
Drug: Prazosin Oral Tablet
Normalized name: prazosin Oral Tablet
DrugBank: Prazosin (DB00457)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-Dose and administration of prazosin: 30 μg/kg/dose of prazosin will be delivered orally every 6 hours 4 doses, in adults we shouldn't exceed 1 mg per dose. Prazosin will be delivered using a nasogastric tube while securing the patient's airway in the event of vomiting or unconsciousness. Every 30 minutes for the first three hours, every hour for the following six, and then every four hours until improvement, blood pressure, pulse rate, respiration rate, and oxygen saturation will be measured. When pain is the only symptom, prophylaxis shouldn't be given. To avoid the first-dose phenomenon, the patient should remain in a laying position for around 3 hours (even while the case is being examined) (Shoreit et al., 2019).
Study: NCT04874545
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Total intravenous inhalational anesthesia
Study: NCT06098625
Drug: Empagliflozin 25 MG
Normalized name: empagliflozin 25 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin 25 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
Study: NCT06098625
Drug: Linagliptin 5 mg Oral Tablet
Normalized name: linagliptin 5 MG Oral Tablet
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: linagliptin 5 mg once a day for 12 months on glycemic outcomes, renal outcomes and body composition in renal transplant recipients with diabetes mellitus
Study: NCT04778982
Drug: KN026 combined with Palbociclib and Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: HR+/HER2-positive MBC will be treated by KN026 20 mg/kg+Palbociclib+fulvestrant 500 mg
Study: NCT04571879
Drug: Nebulized Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized Lidocaine for Reducing Pain of Nasogastric Tube Insertion in Children
Study: NCT04791839
Drug: Zimberelimab
Normalized name: Zimberelimab
DrugBank: Zimberelimab (DB17505)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zimberelimab will be supplied by Arcus Biosciences.
Study: NCT04791839
Drug: Domvanalimab
Normalized name: Domvanalimab
DrugBank: Domvanalimab (DB18848)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domvanalimab will be supplied by Arcus Biosciences.
Study: NCT04791839
Drug: Etrumadenant
Normalized name: Etrumadenant
DrugBank: Etrumadenant (DB17506)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etrumadenant will be supplied by Arcus Biosciences.
Study: NCT05014360
Drug: JNJ-64251330
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64251330 tablets will be administered orally.